My research in cancer pharmacogenomics focuses on the functional translation of precision medicine into clinical practice. Our work is dedicated to unraveling the molecular mechanisms behind acquired therapy resistance in advanced malignancies. By identifying novel therapeutic vulnerabilities, we aim to translate these insights into effective therapeutic approaches that pre-empt resistance and improve long-term outcomes for patients with aggressive cancers.